{{Rsnum
|rsid=2282143
|Gene=SLC22A1
|Chromosome=6
|position=160136611
|Orientation=plus
|GMAF=0.05739
|Gene_s=LOC100289162,SLC22A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 75.2 | 21.9 | 2.9
| JPT | 73.5 | 23.9 | 2.7
| YRI | 83.7 | 16.3 | 0.0
| ASW | 89.5 | 10.5 | 0.0
| CHB | 75.2 | 21.9 | 2.9
| CHD | 69.7 | 28.4 | 1.8
| GIH | 82.2 | 16.8 | 1.0
| LWK | 84.5 | 15.5 | 0.0
| MEX | 96.6 | 3.4 | 0.0
| MKK | 93.6 | 6.4 | 0.0
| TSI | 99.0 | 1.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2282143
|Name_s=SLC22A1: P341L
|Gene_s=SLC22A1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Reduced MPP+ uptake in oocytes
|Drugs=MPP+
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111564
}}

{{GET Evidence
|gene=SLC22A1
|aa_change=Pro341Leu
|aa_change_short=P341L
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2282143
|overall_frequency_n=351
|overall_frequency_d=10758
|overall_frequency=0.0326269
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=7
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|pph2_score=0.979
|nblosum100=7
|autoscore=3
|webscore=N
}}

{{PMID Auto
|PMID=23612856
|Title=Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}